Optiscan has been featured in Small Caps, highlighting the early progression of its first-in-human head and neck cancer imaging study to Stage 2 at St John of God Murdoch Hospital in Perth.

The article notes that the study advanced ahead of schedule following Human Research Ethics Committee approval, with the next phase combining live intraoperative imaging using Optiscan’s InVue precision surgery platform with ex vivo tissue analysis using the InForm digital pathology platform. The report highlights that data generated from the study will support planned US FDA submissions, AI development and broader validation of the company’s imaging platform across multiple tissue types and clinical settings.

CEO and Managing Director Dr. Camile Farah said: “This study is proving to be the perfect vehicle to evaluate our imaging technologies in head and neck cancer surgery within a real-world clinical environment—its Stage 1 deliverables have Optiscan well on the way to demonstrating how real-time microscopic imaging can potentially support surgeons with tissue assessment and surgical decision-making during complex oncological procedures.”

Small Caps – Read the full article here.